Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice

REFERENCES

• Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum. 2005;34:819–36.
   Google Scholar
• Vultaggio A, Matucci A, Nencini F, Pratesi S, Panonchi P, Rossi 0, et al. Anti-infliximab IgE and non-IgE antibodies and induc-tion of infusion-related severe anaphylactic reactions. Allergy. 2010;65:657–61.
   Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for treating rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35–45.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, pla-cebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400–11.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pav-elka K, van Vollenhoven R, et al. A multicenter, randomized, double-blind clinical trial of combination therapy with ada-limumab plus methotrexate versus methotrexate alone or ada-limumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37.
   Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis. 2006;65:753–9.
   PubMed Web of Science ®Google Scholar
• Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan A-N, Walker D, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum. 2008;59:1467–74.
   Google Scholar
• Van Vollenhoven RF, Cifaldi MA, Ray S, Chen N, Weisman MH. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial comparison study. Arthritis Care Res. 2010;62:226–34.
   Google Scholar
• Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Oguchi T, et al. Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) Study. Mod Rheu-matol. 2011;.
   Google Scholar
• HUMIRA (adalimumab) (prescribing information) (in Japanese). Pharmaceuticals and medical devices agency web site. http://www. info.pmda.go.jp/go/pack/3999426G1024_1_12/.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762–84.
   PubMed Web of Science ®Google Scholar
• Van Gestel AM, Haagsma CJ, van Riel PLCM. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998;41:1845–50.
   Google Scholar
• Van Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, Rich B, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. AmericanCollege of Rheumatology European League of Associations for Rheumatology. J Rheumatol. 1999;26:705–11.
   PubMed Web of Science ®Google Scholar
• Shinomiya F, Mima N, Nanba K, Tani K, Nakano S, Egawa H, et al. Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period. Mod Rheu-matol. 2008;18:165–9.
   PubMed Web of Science ®Google Scholar
• Van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewe R, Patra K, et al. Disease activity, physical function, and radiographic progression after long-term therapy with ada-limumab plus methotrexate: 5-year results of PREMIER. J Rheumatol. 2010;37:2237–46.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh A, Weinblatt ME, Patra K, Pangan AL. Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis. 2011.
   Google Scholar
• Miyasaka N, the CHANGE study Investigators. Clinical investi-gation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evalua-tion: the CHANGE study. Mod Rheumatol. 2008;18:252–62.
   Google Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: rela-tionship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007; 66:921–6.
   PubMed Web of Science ®Google Scholar
• Radstake TRDJ, Svenson M, Eijsbouts AM, van den Hoogen FR!, Enevold C, van Riel PLCM, et al. Formation of antibodies against infliximab and adalimumab strongly correlated with functional drug levels and clinical response in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1739–45.
   Google Scholar
• Kaneko A. Case reports of biological products: D. Adalimumab. In: Abe C, Kondo M, Matsubara T, Yamasaki K. Nihon Igaku-kan, editors. The manual of rheumatoid arthritis therapy with biologics. 2010; 69–77.
   Google Scholar
• Kievit W, Adang EM, Fransen J, Kuper HH, van de Laar MAFJ, Jansen TL, et al. The effectiveness and medication costs of threeanti-tumor necrosis factor agents in treating rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis. 2008;67:1229–34.
   Google Scholar
• Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62:22–32.
   PubMed Web of Science ®Google Scholar
• Du Pan SM, Dehler S, Ciurea A, Ziswiler H-R, Gabay C, Finckh A. Comparison of drug retention rates and causes of drug dis-continuation between anti-tumor necrosis factor agents in rheu-matoid arthritis. Arthritis Rheum. 2009;61:560–8.
   Google Scholar
• Gomez-Reino JJ, Garmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006; 8:R29–35.
   Google Scholar
• Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the man-agement of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964–75.
   PubMed Web of Science ®Google Scholar
• Humira® (adalimumab) (prescribing information). Abbott Labo-ratories. North Chicago; 2010.
   Google Scholar
• Paltiel M, Gober LM, Deng A, Mikdashi J, Alexeeva I, Saini SS, et al. Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab. Arch Dermatol. 2008;144:1190–4.
   PubMed Web of Science ®Google Scholar
• Benucci M, Manfredi M, Demoly P, Campi P. Injection site reactions to TNF-a blocking agents with positive skin tests. Allergy. 2008;63:138–9.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861–74.
   Google Scholar